Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx, Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

Fosun Pharma, established in 1994, is a global pharmaceutical and healthcare group based in China.  Fosun Pharma's self-described  business directly operates in pharmaceuticals, medical devices and diagnostics, and healthcare services; it also participates in pharmaceutical distribution through its stake in Guoyao Holding.

Metric
Company Name	Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Ardelyx, Inc.	CanSino Biologics Inc.
Symbol	600.20K	ARDX	6.18K
MSH ID	COM:FOSUNPHARMA	COM:ARDELYX	COM:CANSINOTECH
Market	STOCKS	STOCKS	STOCKS
Sector	Healthcare	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology	Drug Manufacturers - Specialty & Generic
Country	CN	US	CN
Stage		Debt
Employee Count	40.37K	267	1.49K
Website	fosunpharma.com	ardelyx.com	cansinotech.com
LinkedIn			cansino-biotechnology-inc.
Founders

Metric
Market Cap	7.34B	1.30B	833.96M
Enterprise Value
Monthly Web Traffic		33.50K
Web Traffic Growth		2.80
Valuation
Raised Capital		20M

Metric
Revenue	5.66B	124.46M	49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.48B	106.66M	-61.04M
EBITDA	545.06M	-55.35M	-203.86M
Operating Income	116.10M	-63.28M	-236.92M
Net Income	328.22M	-66.07M	-203.94M
EPS	0.12	-0.30	-0.83
Diluted EPS	0.12	-0.30	-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.49	0.86	0.14
Operating Profit Margin	0.10	-0.28	-0.86
EBITDA Margin	0.10	-0.44	-4.15
Net Profit Margin	0.08	-0.31	-1.42
Return on Equity	0.08	-0.40	-0.16
Return on Assets	0.03	-0.19	-0.11
Return on Capital Employed	0.06	-0.21	-0.08

COM:FOSUNPHARMA

Fosun Pharma

Last Close

26.24

25/11 07:00

Market Cap

53.38B

Beta: -

Volume Today

14.02M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	16.58	-74.58
P/B Ratio	1.29	10.37
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.76	14.47	20.35
EV Multiple	11.42	-20.25	-3.00

Metric
Days Sales Outstanding	89.20	117.61	485.87
Days Payables Outstanding	103.66	185.33	170.20
Days Inventory Outstanding	131.85	264.91	251.49
Operating Cycle	221.05	329.52	815.83
Cash Conversion Cycle	121.72	100.07	770.86
Asset Turnover	0.39	0.61	0.07

Metric
Operating Cash Flow	600.15M	-89.72M	-124.92M
Free Cash Flow	-133.89M	-90.06M	-208.89M
Cash Flow to Debt	0.12	-0.77	-0.12
Operating Cash Flow/Sales	0.09	-0.41	-0.43
Free Cash Flow Yield	-0.03	-0.03	-0.25

Metric
Cash & Equivalents	1.34B	21.47M	388.10M
Accounts Receivable	220.77M	-14.30M	36.58M
Inventory	1.04B	12.45M	48.53M
Goodwill	1.49B
Debt to Capitalization	0.42	0.41	0.34
Debt to Assets	0.30	0.12	0.21
Current Ratio	1.01	5.54	2.24
Quick Ratio	0.79	4.36	2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.09
R&D to Revenue	0.11	0.26	1.04
SG&A to Revenue	0.04	0.15	0.34